Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BIOTRONIK AG
The IPO is expected to raise $166m to support R&D of new arrhythmia mapping and ablation technologies and expand commercial operations.
Acute ST-elevation myocardial infarction patients treated with Biotronik’s Orsiro biodegradable polymer sirolimus-eluting stent had a significantly lower rate of target vessel failure than patients treated with Abbott’s Xience durable polymer everolimus-eluting stent at the one-year follow-up in the BIOSTEMI trial.
The company says Biomonitor III documents suspected arrhythmias or unexplained syncope in patients who have experienced cardiac arrhythmias or who are at risk for cardiac arrhythmias.
Results of the SENSE trial showed Biotronik’s DX system, which is available in both ICD and CRT-D devices, can detect atrial high-rate episodes as effectively as dual-chamber ICDs and better than single-chamber ICDs even though it does not have an atrial sensing lead.
- Medical Devices
- Drug Delivery
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive